Problem

Onepot AI addresses the “make” step in small-molecule discovery, where promising drug, material, and agrochemical ideas must be turned into physical compounds for testing. The process remains slow, labor-intensive, and difficult to predict: a typical pharmaceutical company may wait 6–12 weeks for a handful of molecules, most synthesis projects fail on their first attempt, and useful reaction knowledge is fragmented across limited datasets and older literature. Onepot frames this bottleneck as a major contributor to the roughly 10-year, $2 billion cost of developing a drug.

The principal use case is for pharmaceutical and biotech researchers that need custom molecules quickly enough to iterate through the design–make–test–analyze cycle. Instead of waiting months for an external synthesis project or having chemists repeatedly troubleshoot reactions manually, customers can submit target compounds and obtain physical material for biological testing and further discovery.

Product / Service

Onepot is an AI-powered custom-synthesis CRO built around onepot CORE, an enumerated library of billions of potentially make-on-demand molecules. Customers search the library or submit a target molecule, receive a quote, and have the compound synthesized and quality-controlled in Onepot’s US laboratory. The company’s AI chemist, Phil, plans routes, selects reagents and reaction conditions, writes experimental protocols, analyzes LC/MS results, and designs follow-up experiments; robotic equipment then performs liquid handling, synthesis, workup, purification, and QC in a closed loop.

The model combines software, machine-learning feasibility prediction, and automated laboratory execution rather than selling AI recommendations alone. Onepot says its service can deliver small quantities rapidly, with an entry tier of 0.5–1.5 mg per compound at $125 on a success-based basis. Its published operating claims include delivery in as little as five business days, a 70–80% synthesis success rate, and at least 90% purity by LC/MS, positioning the service as a faster and more predictable alternative to conventional custom synthesis.

Market

Onepot competes in the intersection of AI-enabled drug discovery, automated chemical synthesis, and custom small-molecule contract research. Its alternatives include internal medicinal-chemistry teams, conventional synthesis CROs, and automated-chemistry platforms. Public reporting identifies Chemify as a startup competitor and WuXi AppTec as an established pharmaceutical-services competitor; Iktos is also an adjacent AI-and-robotics drug-discovery company. Onepot’s stated differentiation is an emphasis on expanding the reaction and molecule space that can be synthesized, rather than primarily building robotic hardware.

The company appears to be at an early commercial stage rather than a mature scaled CRO. It launched publicly in November 2025 with $13 million from investors including Fifty Years, Khosla Ventures, Speedinvest, Norrsken VC, and Script Capital, and has said that early commercial partners are receiving new molecules 6–10 times faster. Its catalog, automated lab, commercial pricing, and partner claims demonstrate meaningful product validation, but the available evidence does not disclose revenue, customer names, or customer counts, so its commercial scale remains unquantified.